The Princess Margaret Cancer Centre Experience: Transitioning to GCSF Alone for Stem Cell Mobilization in Myeloma Patients

Historically at Princess Margaret Cancer Centre, cyclophosphamide and GCSF was the standard stem cell mobilization regimen used for transplant eligible multiple myeloma patients. Limitations to this regimen included chemotherapy associated toxicity such as febrile neutropenia, and unpredictability regarding the ideal planned apheresis start date. With the recent validation of open-vial sterility of plerixafor allowing for broader access at our centre (Seki et al. Can J Hosp Pharm 2017;70:270), an opportunity was identified to transition to a less toxic GCSF alone mobilization regimen.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research